Objective To analyze the impact of Impact on the extension of survival time and hinder the progression of anti-viral therapy with decompensated cirrhosis. Methods 96 cases of patients with decompensated cirrhosis according to a random number table method were divided into observation group and control group,there were 48 cases in each group,the observation group was treated with antiviral therapy with Nuclear P analogues,the control group was treated with routine treatment,observed the survival situation of patients received antiviral therapy,The incidence of liver cancer of two group were compared. Results The ALT,TBIL of two groups appeared gradually decreased,ALB gradually increased,but the observation group than in the control group (P<0.05),after 24 weeks of treatment,The Child-Plug score of observation group was(7.29±1.13),control group was(8.82±1.33),there was statistical significance(P<0.05);there were some differences in the survival time of treated with different drugs for anti-viral treatment in Observation group,but there was not statistically significant(P>0.05);The number of patients before death which diagnosed with liver cancer was 25 cases(52.1%)significantly greater than observation group 19 cases(39.6%), there was statistical significance(P<0.05),There were 5 patients in treatment of 3TC developed drug-resistance,but no disease aggravation. Conclusion Antiviral treatment decompensated cirrhosis can improve liver function in patients,prolong the survival time of patients,reduce the incidence of liver cancer,and has application value very positive.%目的：探讨抗病毒治疗失代偿肝硬化对延长生存时间及阻碍病情进展的影响。方法将96例失代偿肝硬化患者按照随机数表法分为观察组和对照组，每组48例，对观察组采用核苷类似物进行抗病毒治疗，对照组患者予以常规治疗，观察接受抗病毒治疗者的生存时间情况，比较两组患者的肝癌发生率。结果两组患者ALT、TBIL均出现逐渐下降，ALB逐渐上升，但观察组优于对照组（P＜0.05）；治疗24周后，观察组患者Child-Plug评分为（7.29±1.13）分，对照组为（8.82±1.33）分，差异具有统计学意义（P＜0.05）；观察组采用不同药物进行抗病毒治疗患者的生存时间存在一定差异，但无统计学意义（P＞0.05）；对照组患者死亡前被确诊为肝癌者25例（52.1%）明显多于观察组19例（39.6%），差异具有统计学意义（P＜0.05）；5例接受3TC治疗的患者出现耐药，但病情未加重。结论抗病毒治疗失代偿肝硬化可有效改善患者的肝功能，延长患者生存时间，降低肝癌发生率，具有非常积极的应用价值。
展开▼
